Cargando…
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response
Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together with rarer cutaneous cancers, such as Merkel cell carcinoma (MCC) and other forms of adnexal cancers....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225110/ https://www.ncbi.nlm.nih.gov/pubmed/35743435 http://dx.doi.org/10.3390/jcm11123364 |
_version_ | 1784733538972598272 |
---|---|
author | Zelin, Enrico Maronese, Carlo Alberto Dri, Arianna Toffoli, Ludovica Di Meo, Nicola Nazzaro, Gianluca Zalaudek, Iris |
author_facet | Zelin, Enrico Maronese, Carlo Alberto Dri, Arianna Toffoli, Ludovica Di Meo, Nicola Nazzaro, Gianluca Zalaudek, Iris |
author_sort | Zelin, Enrico |
collection | PubMed |
description | Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together with rarer cutaneous cancers, such as Merkel cell carcinoma (MCC) and other forms of adnexal cancers. The majority of NMSCs can be successfully treated with surgery or radiotherapy, but advanced and metastatic stages may require systemic approaches such as immunotherapy with immune checkpoint inhibitors (ICIs). Summary: Since immunotherapy is not effective in all patients and can potentially lead to severe adverse effects, an important clinical question is how to properly identify those who could be suitable candidates for this therapeutic choice. In this paper, we review the potential features and biomarkers used to predict the outcome of ICIs therapy for NMSCs. Moreover, we analyze the role of immunotherapy in special populations, such as the elderly, immunocompromised patients, organ transplant recipients, and subjects suffering from autoimmune conditions. Key messages: Many clinical, serum, histopathological, and genetic features have been investigated as potential predictors of response in NMSCs treated with ICIs. Although this field of research is very promising, definitive, cost-effective, and reproducible biomarkers are still lacking and further efforts are needed to validate the suggested predictors in larger cohorts. |
format | Online Article Text |
id | pubmed-9225110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92251102022-06-24 Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response Zelin, Enrico Maronese, Carlo Alberto Dri, Arianna Toffoli, Ludovica Di Meo, Nicola Nazzaro, Gianluca Zalaudek, Iris J Clin Med Review Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together with rarer cutaneous cancers, such as Merkel cell carcinoma (MCC) and other forms of adnexal cancers. The majority of NMSCs can be successfully treated with surgery or radiotherapy, but advanced and metastatic stages may require systemic approaches such as immunotherapy with immune checkpoint inhibitors (ICIs). Summary: Since immunotherapy is not effective in all patients and can potentially lead to severe adverse effects, an important clinical question is how to properly identify those who could be suitable candidates for this therapeutic choice. In this paper, we review the potential features and biomarkers used to predict the outcome of ICIs therapy for NMSCs. Moreover, we analyze the role of immunotherapy in special populations, such as the elderly, immunocompromised patients, organ transplant recipients, and subjects suffering from autoimmune conditions. Key messages: Many clinical, serum, histopathological, and genetic features have been investigated as potential predictors of response in NMSCs treated with ICIs. Although this field of research is very promising, definitive, cost-effective, and reproducible biomarkers are still lacking and further efforts are needed to validate the suggested predictors in larger cohorts. MDPI 2022-06-11 /pmc/articles/PMC9225110/ /pubmed/35743435 http://dx.doi.org/10.3390/jcm11123364 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zelin, Enrico Maronese, Carlo Alberto Dri, Arianna Toffoli, Ludovica Di Meo, Nicola Nazzaro, Gianluca Zalaudek, Iris Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response |
title | Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response |
title_full | Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response |
title_fullStr | Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response |
title_full_unstemmed | Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response |
title_short | Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response |
title_sort | identifying candidates for immunotherapy among patients with non-melanoma skin cancer: a review of the potential predictors of response |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225110/ https://www.ncbi.nlm.nih.gov/pubmed/35743435 http://dx.doi.org/10.3390/jcm11123364 |
work_keys_str_mv | AT zelinenrico identifyingcandidatesforimmunotherapyamongpatientswithnonmelanomaskincancerareviewofthepotentialpredictorsofresponse AT maronesecarloalberto identifyingcandidatesforimmunotherapyamongpatientswithnonmelanomaskincancerareviewofthepotentialpredictorsofresponse AT driarianna identifyingcandidatesforimmunotherapyamongpatientswithnonmelanomaskincancerareviewofthepotentialpredictorsofresponse AT toffoliludovica identifyingcandidatesforimmunotherapyamongpatientswithnonmelanomaskincancerareviewofthepotentialpredictorsofresponse AT dimeonicola identifyingcandidatesforimmunotherapyamongpatientswithnonmelanomaskincancerareviewofthepotentialpredictorsofresponse AT nazzarogianluca identifyingcandidatesforimmunotherapyamongpatientswithnonmelanomaskincancerareviewofthepotentialpredictorsofresponse AT zalaudekiris identifyingcandidatesforimmunotherapyamongpatientswithnonmelanomaskincancerareviewofthepotentialpredictorsofresponse |